ReviewWorld journal of transplantation2026

Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation.

Pranjal Kashiv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.